Year
2023
-
MHRA Authorizes Cosentyx for Two Forms of Juvenile Arthritis
-
Neurotech’s Treatment for Macular Telangiectasia Shows Promise in Trial
-
EQRx Drops U.S. Plans for NSCLC Therapy
-
FDA Approves AstraZeneca’s Imfinzi and Imjudo for Stage 4 NSCLC
-
Stada and Xbrane Get EU Approval for Lucentis Biosimilar for Eye Disease
-
Satsuma STS101 Migraine Candidate Fails Late-Stage Trial
-
GSK Limits Ovarian Cancer Drug’s Indication
-
Seagen’s Adcetris Gains Expanded Label for Pediatric Cancer Patients
-
How high blood sugar REALLY causes type 2 diabetes: Chemicals produced when glucose is broken down are to blame, study finds
-
FDA Accepts New Drug Application for Zilucoplan for Generalized FDA Accepts New Drug Application for Zilucoplan for Generalized Myasthenia GravisGravis